Two transactions further strengthen HIV pipeline and outlook 18 December 2015, London – GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the […]
Program expands access to care supporting the Diagnostics Access Iniative Basel, 26 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Global Access Program for HIV viral load testing, created in partnership with UNAIDS, the joint United Nations Program on HIV/AIDS, the Clinton Health Access Initiative (CHAI), the […]
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays Basel, 2 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets accepting the CE mark. The […]
— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]
Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]
Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks Additional Presentations of Preclinical Data at Annual Meeting of European Society of Gene and Cell Therapy (ESGCT) RICHMOND, Calif., Oct. 28, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data demonstrating sustained control of HIV viral load (VL) at […]